Loading
Amplifon Publication of the Minutes of the Ordinary Shareholders’ Meeting Stock: price and insider trades · Italy
Amplifon Publication of the Minutes of the Ordinary Shareholders’ Meeting: what insiders have been doing
Amplifon Publication of the Minutes of the Ordinary Shareholders’ Meeting has a thin disclosure history in our data (latest filing: 15 May 2026). New filings will appear here as soon as they are published. Every figure here comes from the filings published by Consob and describes the past, not future prices; it is not investment advice.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Amplifon Publication of the Minutes of the Ordinary Shareholders’ Meeting Buy (bullish), based on 16 analysts. Average price target: €13.44.
Fundamental score
Ranked 9,763 of 24,148 companies
56.4
score / 100
Value64
Quality49
FCF yld9.8%
Earn yld3.0%
EV/EBITDA9.6x
ROE5.7%
Gross mgn53%
Net mgn3.8%
Debt/EBITDA3.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€12.15
Analyst consensus
16 analystsBuy
€11.00Target €13.44(+11%)€16.70
Income statement
Revenue€2.4B
Gross profit€1.3B53% margin
EBITDA€506.5M21% margin
Net income€91.3M3.0% margin
Valuation
PER (trailing)39.2x
PER (forward)13.8x
P/Book2.1x
Beta0.99
Balance sheet & cash
Market cap€3.0B
Total debt€1.8B
Free Cash Flow€296.4M
Debt / Equity118%
Profitability & ownership
ROE5.7%
ROA3.8%
% insiders35.0%
% institutions21.5%
Last declaration on 15 May 2026
About Amplifon Publication of the Minutes of the Ordinary Shareholders’ Meeting
Amplifon S.p.A. is a global benchmark in hearing care, listed on Borsa Italiana (FTSE MIB) in Italy and headquartered in Milan. Founded in 1950 by Algernon Charles Holland, the company was originally created to help people who had suffered hearing damage after the war. Over time, it evolved from a local Italian specialist into a multinational hearing-solutions group with a highly recognized retail and clinical footprint. Today, Amplifon positions itself as the world leader in hearing care services and solutions, and its brand strength, service model and geographic diversification are central to its investment case. ([corporate.amplifon.com](https://corporate.amplifon.com/en/our-identity/our-history?utm_source=openai))
The group’s core business is built around the distribution, fitting and aftercare of hearing aids, supported by accessories, hearing tests, personalized consultations and ongoing patient services. Amplifon operates across three major regions — EMEA, the Americas and APAC — using a business-to-consumer model in most markets, while also running two US-specific models: franchising and managed care. This structure gives the company both local proximity and global scale, allowing it to combine clinical expertise, brand equity and recurring customer relationships. In an industry where trust, service quality and long-term customer engagement matter more than pure product hardware, Amplifon’s service-oriented model is a meaningful competitive advantage. ([corporate.amplifon.com](https://corporate.amplifon.com/en/hearing-care-leader/global-operations?utm_source=openai))
Read moreShow less
Amplifon’s competitive position is reinforced by its broad international presence and dense distribution network. Corporate materials indicate close to 10,000 points of sale across 25 to 26 countries and more than 20,000 employees, making it one of the most scaled players in the sector. The US is now the company’s largest revenue market, underscoring the strategic importance of North America in the group’s growth profile. Amplifon continues to expand in the US through bolt-on acquisitions and network development, including acquisitions in Pennsylvania in 2024 and Arizona in 2025, which strengthened both direct retail and franchise capabilities. The Miracle-Ear brand remains a key asset in that market. ([corporate.amplifon.com](https://corporate.amplifon.com/en/media/news/CHA_2026?utm_source=openai))
Recent developments point to a company balancing growth and margin discipline. In 2025, Amplifon reported consolidated revenues of about EUR 2.4 billion, with a notable improvement in organic growth in the second half of the year. Management also launched the Fit4Growth program to improve margins, optimize the store network, reduce costs and prioritize higher-return investments. In early 2026, the company reported a strong first quarter with renewed organic growth and record adjusted EBITDA margin, while the April 2026 shareholders’ meeting approved the 2025 financial statements and a dividend of EUR 0.29 per share. For international investors, Amplifon remains a defensive healthcare-services name on Borsa Italiana (FTSE MIB) in Italy, combining structural demand, recurring service revenues and a long runway for international expansion. ([corporate.amplifon.com](https://corporate.amplifon.com/en/investors/press-releases/f-pr-FY-2025-results-04-03-2026?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
